Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MYC | P01106 | 4/20 | 0.52 |
| ▸ | MAX | P61244 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31215378 | 1.00 | TSHR (0.56) | TSHRMYCMAXMEN1POLB | |
| SCHEMBL458099 | 0.87 | ALDH1A1 (0.51) | MEN1POLBKMT2AAKR1C3AKR1C2 | |
| SCHEMBL31215377 | 0.83 | SLC22A12 (0.66) | MEN1KMT2ASLC22A12RXRARXRB | |
| SCHEMBL459394 | 0.83 | SLC22A12 (0.66) | MEN1KMT2ASLC22A12RXRARXRB | |
| SCHEMBL528177 | 0.82 | MYC (0.67) | TSHRMYCMAXMEN1POLB | |
| SCHEMBL30082870 | 0.82 | MYC (0.67) | TSHRMYCMAXMEN1POLB | |
| SCHEMBL3537490 | 0.80 | MAPT (0.62) | TSHRMYCMAXPOLBCASP6 | |
| SCHEMBL459191 | 0.79 | MRGPRX4 (0.55) | SLC22A12RXRARXRBRXRG | |
| SCHEMBL458511 | 0.79 | SLC22A12 (0.51) | SLC22A12RXRARXRBRXRGHTT | |
| SCHEMBL31215352 | 0.79 | CA12 (0.59) | TSHRSLC22A12RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-10-02 | — | — | US | claimed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | claimed |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-12 | — | — | US | claimed |
| WO-2012033720-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-15 | — | — | WO | claimed |
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012033720-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | FPR1, FFAR1, GLS | TSHR 1239/4885MYC 3784/4885MAX 1757/4885 |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | GLS, NLRP3, XDH | TSHR 1920/4885MYC 4316/4885MAX 2230/4885 |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | FPR1, FFAR1, GLS | TSHR 1239/4885MYC 3784/4885MAX 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.